Topics:
Gastrointestinal Cancers • Medical Oncology • Hepatocellular Carcinoma • Journal Club ft. NEJM publications
What clinical factors influence your first line treatment selection in advanced HCC?
Are there factors which would make you more likely to use atezo/bev vs durva/treme vs TKI?
Answer from: Medical Oncologist at Academic Institution
With now many options of therapy for the treatment of advanced HCC, this is good news. It is also a challenge of how to pick and choose, and what factors may influence the choice of first line treatment.The possible choices would be either the combination of checkpoint inhibitor plus an add-on thera...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Per above, assessment of varices to make sure there are no bleeding issues that would preclude the use of bevacizumab. Performance status and co-morbidities are critical as are lab values. Multidisciplinary assessment is important for individuals who do not have extrahepatic disease. TKIs tend to ha...
Answer from: Medical Oncologist at Academic Institution
The main determinant of treating liver cancer patients is still the underlying liver function. For those patients with intact liver function, all treatment options remain available. For those with decompensated liver function, options for active anticancer therapy are limited or in many cases not pu...